RecruitingPhase 1NCT06206824

Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease

Studying Down syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Perha Pharmaceuticals
Intervention
Leucettinib-21(drug)
Enrollment
164 enrolled
Eligibility
18-45 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

France 2030 program · European Innovation Council · Fondation Jérôme Lejeune

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06206824 on ClinicalTrials.gov

Other trials for Down syndrome

Additional recruiting or active studies for the same condition.

See all trials for Down syndrome →

← Back to all trials